|
Title
|
Opportunity Number
|
Funding Agency
|
Deadline
|
|
New Therapeutic Strategies for Genital Herpes
|
Opportunity Number
RFA-AI-24-068
|
Funding Agency
NIH
|
Deadline
Jan 1 2025
|
|
New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services
|
Opportunity Number
RFA-DA-25-072
|
Funding Agency
NIH
|
Deadline
Mar 19 2025
|
|
Assay Validation of High Quality Markers for Clinical Studies in Cancer
|
Opportunity Number
PAR-25-074
|
Funding Agency
NCI
|
Deadline
Feb 14 2025
|
|
Artificial Intelligence and Machine Learning Applied to Nuclear Science and Technology
|
Opportunity Number
DE-FOA-0003458
|
Funding Agency
DE
|
Deadline
Jan 14 2025
|
|
Neurological Effects of Infection-Associated Chronic Illnesses
|
Opportunity Number
PAR-25-116
|
Funding Agency
NIH
|
Deadline
Jan 5 2025
|
|
Morris K. Udall Discovery Centers without Walls (DCWoW) for Parkinson's Disease Research
|
Opportunity Number
NOT-NS-24-061
|
Funding Agency
NIH
|
Deadline
Forecasted
|
|
BAA for Extramural Biomedical and Human Performance Research
|
Opportunity Number
HT9425-23-S-SOC1
|
Funding Agency
DoD
|
Deadline
Jul 31 2028
|
|
FY25 Long Range BAA for Navy and Marine Corps Science and Technology
|
Opportunity Number
N0001425SB001
|
Funding Agency
DoD
|
Deadline
Sep 30 2025
|
|
Discovery and Development of Natural Products for Cancer Interception and Prevention
|
Opportunity Number
RFA-CA-25-013
|
Funding Agency
NIH
|
Deadline
May 14 2025
|
|
Carderock BAA
|
Opportunity Number
NSWCCD-25-S-0001
|
Funding Agency
DoD
|
Deadline
Feb 28 2025
|
|
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility
|
Opportunity Number
PA-25-123
|
Funding Agency
NCI
|
Deadline
Feb 16 2025
|
|
CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin
|
Opportunity Number
PA-25-093
|
Funding Agency
NIH
|
Deadline
Feb 16 2025
|
|
HEAL Initiative: Understanding Individual Differences in Human Pain Conditions
|
Opportunity Number
RFA-NS-25-020
|
Funding Agency
NIH
|
Deadline
Feb 6 2025
|
|
Interventions to expand cancer screening in populations that experience health disparities
|
Opportunity Number
PAR-23-170
|
Funding Agency
NIH
|
Deadline
Feb 5 2025
|
|
Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders
|
Opportunity Number
PAR-25-050
|
Funding Agency
NIH
|
Deadline
Jan 21 2025
|
|
Human Brain Single-cell Genomics Explorer
|
Opportunity Number
RFA-NS-24-038
|
Funding Agency
NIH
|
Deadline
Jan 14 2025
|
|
Development of Alternative Human Models of Radiation-Induced Injuries
|
Opportunity Number
RFA-AI-24-067
|
Funding Agency
NIH
|
Deadline
Jan 7 2025
|
|
Biologic-based Drug Discovery and Development for Disorders of the Nervous System
|
Opportunity Number
PAR-24-294
|
Funding Agency
NIH
|
Deadline
Dec 27 2024
|
|
Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia
|
Opportunity Number
RFA-NS-25-010
|
Funding Agency
NIH
|
Deadline
Dec 24 2024
|
|
Centers for Precision Disease Modeling
|
Opportunity Number
PAR-24-305
|
Funding Agency
NIH
|
Deadline
Dec 15 2024
|
|
Biomedical Research And Diving Equipment Development
|
Opportunity Number
N0002425R4305
|
Funding Agency
NAVSEA
|
Deadline
Nov 30 2024
|
|
Novel Therapeutics for Select Fungal Pathogens
|
Opportunity Number
RFA-AI-24-065
|
Funding Agency
NIH and NIAID
|
Deadline
Dec 29 2024
|
|
Interventions to Reduce Sleep Health Disparities
|
Opportunity Number
PAR-24-110
|
Funding Agency
NIH
|
Deadline
Jan 7 2025
AIDS
|
|
Interventions to Reduce Sleep Health Disparities
|
Opportunity Number
PAR-24-110
|
Funding Agency
NIH
|
Deadline
Feb 5 2025
Non-AIDS
|
|
Optimizing Behavioral Sleep Interventions
|
Opportunity Number
RFA-MH-25-130
|
Funding Agency
NIH
|
Deadline
May 14 2025
|
|
NICHD Resource Program Grants in Bioinformatics
|
Opportunity Number
PAR-24-301
|
Funding Agency
NIH
|
Deadline
Nov 25 2024
|
|
Studies to Enable Analgesic Discovery
|
Opportunity Number
RFA-NS-25-023
|
Funding Agency
NIH
|
Deadline
Nov 27 2024
|
|
Small Molecule Drug Discovery and Development of Disorders of the Nervous System
|
Opportunity Number
PAR-25-051
|
Funding Agency
NIH
|
Deadline
Nov 26 2024
|
|
Improving Mental and Behavioral Health Topical
|
Opportunity Number
Pre-Announcement
|
Funding Agency
PCORI
|
Deadline
Dec 3 2024
Forecasted
|
|
U.S.-South Africa Program for Collaborative Biomedical Research-Phase 3
|
Opportunity Number
RFA-AI-24-023
|
Funding Agency
NIH
|
Deadline
Feb 12 2025
|
|
NextGen Oral Formulation Vaccines for COVID-19
|
Opportunity Number
RRPV 24-02-OralV
|
Funding Agency
BARDA
|
Deadline
Nov 15 2024
|
|
Viral Infections in the Young Lung
|
Opportunity Number
NOT-HL-24-027
|
Funding Agency
NIH
|
Deadline
Jun 1 2025
Forecasted
|
|
SBIR Phase IIB for Technologies for Heart Lung and Sleep Diseases
|
Opportunity Number
NOT-HL-24-030
|
Funding Agency
NIH
|
Deadline
Feb 25 2025
Forecasted
|
|
Eliminating HIV Proteins
|
Opportunity Number
RFA-AI-24-064
|
Funding Agency
NIH
|
Deadline
Nov 4 2024
|
|
Secondary Analysis of Existing Datasets
|
Opportunity Number
PAR-23-036
|
Funding Agency
NIH
|
Deadline
Feb 28 2025
|
|
Cancer Risk after Bariatric Surgery
|
Opportunity Number
PAR-25-044
|
Funding Agency
NIH/NCI
|
Deadline
Jan 16 2025
|
|
Glioblastoma Research Program (GBMRP)
|
Opportunity Number
HT942524GBMRP
|
Funding Agency
CDMRP
|
Deadline
Nov 6 2024
|
|
Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability
|
Opportunity Number
RPP-24-08-mRNALongTerm
|
Funding Agency
BARDA
|
Deadline
Dec 16 2024
|
|
NICHD Small Research Grant Program (R03 Clinical Trial Required)
|
Opportunity Number
PA-21-221
|
Funding Agency
NIH
|
Deadline
Jan 7 2025
|
|
NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)
|
Opportunity Number
PA-21-231
|
Funding Agency
NIH
|
Deadline
Jan 7 2025
|
|
Research Interests of the Air Force Office of Scientific Research
|
Opportunity Number
FA9550-23-S-0001
|
Funding Agency
Air Force Office of Scientific Research (AFOSR)
|
Deadline
Open until closed
|
|
Army Applications Lab Broad Agency Announcement For Disruptive Applications
|
Opportunity Number
W911NF-24-S-0008
|
Funding Agency
DEVCOM
|
Deadline
Apr 4 2029
|
|
DEVCOM Army Research Laboratory Broad Agency Announcement for Foundational Research
|
Opportunity Number
W911NF-23-S-0001
|
Funding Agency
DEVCOM
|
Deadline
Nov 20 2027
|
|
Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA)
|
Opportunity Number
HDTRA1-24-S-0002
|
Funding Agency
DTRA
|
Deadline
Apr 28 2029
|
|
Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R21 Clinical Trials Not Allowed)
|
Opportunity Number
RFA-DA-26-008
|
Funding Agency
NIH
|
Deadline
Feb 12 2025
|
|
The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 Clinical Trial Optional)
|
Opportunity Number
RFA-CA-25-011
|
Funding Agency
NIH
|
Deadline
Nov 10 2024
|
|
The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R21 Clinical Trial Optional)
|
Opportunity Number
RFA-CA-25-012
|
Funding Agency
NIH
|
Deadline
Nov 10 2024
|
|
NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and Craniofacial Research Workforce (F99/K00 Independent Clinical Trial Not Allowed)
|
Opportunity Number
PAR-24-139
|
Funding Agency
NIH
|
Deadline
Dec 8 2024
|
|
Research on Traumatic Brain Injury (TBI) As a Lifelong Condition
|
Opportunity Number
HHS-2025-ACL-NIDILRR-DPHF-0117
|
Funding Agency
DHHS
|
Deadline
Forecasted
|
|
Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
|
Opportunity Number
PAR-24-036
|
Funding Agency
NIAMS
|
Deadline
Nov 1 2024
|
|
Advancing Strategies to Deliver and Sustain Evidence-Based Chronic Disease Self-Management Education Programs to Support Older Adults with Behavioral Health Conditions
|
Opportunity Number
HHS-2025-ACL-AOA-CSSG-0010 (FORECASTED)
|
Funding Agency
DHHS
|
Deadline
Forecasted
|
|
Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)
|
Opportunity Number
PAR-22-182
|
Funding Agency
NIH
|
Deadline
Feb 19 2025
|
|
Arthritis Research Program (ATRP)
|
Opportunity Number
HT942524ATRPCRA
|
Funding Agency
CDMRP
|
Deadline
Oct 30 2024
|
|
Notice of Special Interest (NOSI): Promoting Data Reuse for Health Research
|
Opportunity Number
NOT-OD-24-096
|
Funding Agency
NIH
|
Deadline
Nov 4 2024
|
|
Notice of Intent to Publish a Funding Opportunity Announcement for RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)
|
Opportunity Number
NOT-CA-24-053
|
Funding Agency
NIH
|
Deadline
Nov 5 2024
|
|
BRAIN Initiative: Production and distribution facilities for brain cell type-specific access reagents (U24 Clinical Trial Not Allowed)
|
Opportunity Number
RFA-MH-25-105
|
Funding Agency
NIH
|
Deadline
Sep 30 2025
|
|
BRAIN Initiative: Scaled reagent resources for brain cell type-specific access across vertebrate species (U01 Clinical Trial Not Allowed)
|
Opportunity Number
RFA-MH-25-100
|
Funding Agency
NIH
|
Deadline
Dec 15 2024
|
|
Engineering of Biomedical Systems
|
Opportunity Number
PD-23-5345
|
Funding Agency
U.S. National Science Foundation (NSF)
|
Deadline
Throughout the year 2024
|
|
Biosensing
|
Opportunity Number
PD-20-7909
|
Funding Agency
U.S. National Science Foundation (NSF)
|
Deadline
Throughout the year 2024
|
|
Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional
|
Opportunity Number
RFA-CA-24-006
|
Funding Agency
NIH
|
Deadline
Nov 3 2024
|
|
ARPA-H Health Science Futures Office Innovative Solutions Opening (ISO)
|
Opportunity Number
ARPA-H-SOL-24-104
|
Funding Agency
ARPA-H
|
Deadline
Mar 15 2025
|
|
ARPA-H Resilient Systems Office Office-wide Innovative Solutions Opening (ISO)
|
Opportunity Number
ARPA-H-SOL-24-103
|
Funding Agency
ARPA-H
|
Deadline
Mar 15 2025
|
|
Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
|
Opportunity Number
PAR-24-036
|
Funding Agency
NIH
|
Deadline
Nov 1 2024
|
|
Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
|
Opportunity Number
PAR-24-035
|
Funding Agency
NIH
|
Deadline
Nov 1 2024
|
|
2024 Human Exploration Research Opportunities (HERO) Overview
|
Opportunity Number
80JSC024NA001
|
Funding Agency
NASA Johnson Space Center
|
Deadline
Oct 30 2024
|
|
Broad Agency Announcement Research and Development In Support of The Joint Program Executive Office For Chemical, Biological, Radiological And Nuclear Defense (JPEO-CBRND), JPM MEDICAL AND JPL EB
|
Opportunity Number
W911SR-22-R-CBRN
|
Funding Agency
DOD
|
Deadline
Jun 26 2027
|
|
Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)
|
Opportunity Number
NOT-HL-20-814
|
Funding Agency
NIH (NHLBI)
|
Deadline
Dec 21 2024
|
|
Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
|
Opportunity Number
RFA-HL-23-010
|
Funding Agency
NIH (NHLBI)
|
Deadline
Dec 21 2024
|
|
Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)
|
Opportunity Number
RFA-HL-23-013
|
Funding Agency
NIH (NHLBI)
|
Deadline
Dec 21 2024
|
|
Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)
|
Opportunity Number
RFA-HL-23-014
|
Funding Agency
NIH (NHLBI)
|
Deadline
Dec 22 2024
|
